Date: 2014-07-30
Type of information: IPO
Company: Innocoll (Ireland)
Investors: Sofinnova Partners (France)
Amount: $ 51.5 million (€ 38.4 million)
Funding type: IPO
Planned used: Innocoll, a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, intends to use the net proceeds from the offering to develop XaraColl® for the treatment of post-operative pain; Cogenzia® for the adjuvant treatment of diabetic foot infections; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The funds will also be used to expand Innocoll's manufacturing infrastructure.
Others: * On July 30, 2014, Innocoll, a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, announced the closing of its public offering of 6,500,000 American Depositary Shares, each representing 1/13.25 ordinary shares, at a public offering price of $9.00 per ADS. As part of the public offering, Sofinnova Venture Partners VIII purchased an aggregate of 1,666,667 ADSs at the public offering price. Sofinnova will have a right to nominate one member to the Company's supervisory board. All of the ADSs were offered by the Company. The Company's ADSs are listed on The NASDAQ Global Market under the symbol "INNL". In addition, the Company has granted the underwriters an option until August 23, 2014 to purchase up to an additional 975,000 ADSs at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. Piper Jaffray & Co. and Stifel acted as joint book-running managers for the public offering. JMP Securities acted as lead manager for the public offering.
Therapeutic area: Medical devices
